Table 3.
Logistic regression analysis of factors associated with treatment failure, Bahir Dar, Nov, 2017–April, 2018
| Variable | Treatment failure | Total | COR (95%CI), P | AOR (95%CI), P | ||
| Category | Yes, n (%) | No, n (%) | n (%) | |||
| Gender | Female | 17 (26.2) | 232 (63.6) | 263(61.2) | 1.00 | |
| Male | 48 (73.8) | 133 (36.4) | 167(38.8 | 4.9(2.2–8.9),0.0 | 2.9(1.45–9)0.002 | |
| BMI Category |
<18.5 | 23(35.4) | 72(19.7) | 95(22.1) | 1.00 | 1.00 |
| 18.6 –25.5 | 38(58.5) | 222(60.8) | 260(60.5) | 0.5(0.29–0.9)0.04 | 1.00 | |
| 25.6–30.0 | 4(6.2) | 67(18.4) | 71(16.5) | 0.1(0.06–0.5)0.003 | 1.00 | |
| >30.0 | 0.0(0 )0.0 | 4(0.9) | 4(0.9) | 1.00 | 1.00 | |
| Marital status |
Married | 22(33.8) | 174(47.7) | 196(45.6) | 1.1(.4–2.8).7 | 0.7(0.2–2.1)0.5 |
| single | 15(23.1) | 56(15.3) | 71(16.5) | 1.6(0.8–3.4)0.04 | 0.7(0.2–3.0)0.6 | |
| Divorced | 21(32.3) | 72(19.7) | 93(21.6) | 2.3(1.1–4.4) 0.04 | 1.0(0.3–3.6)0.9 | |
| Widowed | 7(10.8) | 63(17.3) | 70(16.3) | 1.00 | ||
| Current TB | Yes | 4(6.2) | 40(11.0) | 44(10.2) | 0.5(0.1–1.5)0.2 | 2.3(0.6–9.3)0.2 |
| No | 61(93.8) | 325(89.0) | 386(89.8) | 1.00 | ||
| Treated with TB before |
yes | 16(24.6) | 103(28.2) | 119(27.7) | 0.8(0.4–1.5)0.5 | 1.5(0.6–3.4)0.3 |
| No | 49(75.4) | 262(71.8) | 311(72.3) | 1.00 | ||
| Sexual behavior |
0 or 1 sexual contact |
27(41.5) | 287(78.6) | 314(73.0) | 1.00 | |
| ≥ 2 sexual contact |
38(58.5) | 78(21.4) | 116(27.0) | 5.1(2.9–9.0) .0 | 3.2(1.6–6.2)0.0 | |
| Condom use habit | yes | 13(20.0) | 110(30.1) | 123(28.6) | ||
| No | 52(80.0) | 255(69.9) | 307(71.4) | 1.7(0.9–3.2)0.09 | ||
| Types of baseline regimen |
1a | 7(10.8) | 56(15.3 | 63(14.7) | 1.00 | |
| 1b | 2(3.1) | 12(3.3) | 14(3.3) | 1.3(.2–7.2) 0.73 | ||
| 1c | 27(41.5) | 106(29) | 133(30.9) | 2.0(.8–5.0) 0.11 | ||
| 1d | 8(12.3) | 26(7.1) | 34(7.9) | 2.4(.8–7.5) 0.11 | ||
| 1e | 15(23.1) | 134(36.7) | 149(34.7) | 0.8(.3–2.3) 0.82 | ||
| 1f | 6(9.2) | 31(8.5) | 37(8.6) | 1.5(.4–5.01) 0.46 | ||
| Were regimen changed? |
No | 59(90.8) | 295(80.8) | 354(82.3) | 2.3(.9–5.6)0.06 | |
| Yes | 6(9.2) | 70(19.2) | 76(17.7) | |||
| Baseline WHO staging |
1 | 7(10.8) | 53(14.5) | 60(14.0) | 1.00 | |
| 2 | 8(12.3) | 51(14.0) | 59(13.7) | 1.1(0.40–3.5)0.75 | ||
| 3 | 39(60.0) | 228(62.5) | 267(62.1) | 1.2(0.5–3.0)0.55 | ||
| 4 | 11(16.9) | 33(9.0) | 44(10.2) | 2.5(0.8–7.1)0.08 | ||
| Baseline CD4 count |
<200 | 46(70.8) | 169(46.3) | 215(50.0) | 2.8(1.5–4.9) .00 | 2.4(1.0–5.5)0.03 |
| ≥ 200 | 19(29.2) | 196(53.7) | 215(50.0) | |||
| Current CD4 Count | <200 | 20(30.8) | 49(13.4) | 69(16.0) | 2.8(1.5–5.2) .001 | 4.3(1.8–10.0)0.01 |
| ≥ 200 | 45(69.2) | 316(86.6) | 361(84.0) | |||
| Adherence | Good | 14(21.5) | 319(87.4) | 333(77.4) | 1.00 | |
| Fair & Poor | 51(78.5) | 46(12.6) | 97(22.6) | 25.2(12.949.2)0.001 | 16.5(8.2–33.1)0.00 | |
| Time of drug use |
Irregular time |
54(83.1) | 131(35.9) | 185(43) | 8.7(4.4–17.3)0.00 | 3.7(1.7–8.1)0.001 |
| Exact time | 11(16.9) | 234(64.1) | 245(57) | 1.00 | ||